Related Experiment Video

Updated: Oct 11, 2025

Investigating the Pathogenesis of MYH7 Mutation Gly823Glu in Familial Hypertrophic Cardiomyopathy using a Mouse Model
03:45

Investigating the Pathogenesis of MYH7 Mutation Gly823Glu in Familial Hypertrophic Cardiomyopathy using a Mouse Model

Published on: August 8, 2022

3.8K

COVID-19 in Adults With Hypertrophic Cardiomyopathy

Milla E Arabadjian1, Maria C Reuter2, Alexandra Stepanovic2

  • 1New York University Rory Meyers College of Nursing, New York, NY, United States.

Frontiers in Cardiovascular Medicine
|December 3, 2021
PubMed

Insights

Patients with hypertrophic cardiomyopathy (HCM) experienced COVID-19 similarly to the general population. Established risk factors like obesity, not HCM alone, were key drivers of severe COVID-19 outcomes.

Area of Science:

  • Cardiology
  • Infectious Diseases
  • Genetics

Background:

  • Cardiovascular disease (CVD) patients face higher risks for severe COVID-19.
  • The impact of COVID-19 on hypertrophic cardiomyopathy (HCM) patients remains unclear.
  • HCM is a genetic heart condition affecting heart muscle structure.

Purpose of the Study:

  • To investigate the clinical course and outcomes of COVID-19 in patients with HCM.
  • To identify factors influencing COVID-19 severity in HCM patients.

Main Methods:

  • Retrospective observational study of adult HCM patients with SARS-CoV-2 infection.
  • Data collected from a large urban hospital system (January 2020 - January 2021).
  • Included patients with positive PCR or antibody tests for SARS-CoV-2.

Main Results:

  • Seventy HCM patients (mean age 60.1 years, 55.7% male, 60% white) were analyzed.
  • High prevalence of comorbidities: hypertension (64.3%), obesity (52.9%), atrial fibrillation, sleep apnea, and diabetes.
  • Most patients recovered (64.3%); 20% hospitalized, 4.3% required mechanical ventilation, with a 2.9% case fatality rate.
  • Complications included pulmonary embolism, atrial fibrillation, and heart failure.

Conclusions:

  • COVID-19 outcomes in HCM patients were influenced by traditional risk factors like obesity.
  • HCM itself may not be the primary determinant of severe COVID-19 morbidity and mortality.
  • Further research is needed to understand the interplay between HCM, COVID-19, and associated risk factors.

Keywords:
COVID-19hypertrophic cardiomyopathyobesityoutcomesrisk

More Related Videos

Scanning Electron Microscopy of Macerated Tissue to Visualize the Extracellular Matrix10:21

Scanning Electron Microscopy of Macerated Tissue to Visualize the Extracellular Matrix

Published on: June 14, 2016

10.2K
An Approach to Study Shape-Dependent Transcriptomics at a Single Cell Level06:02

An Approach to Study Shape-Dependent Transcriptomics at a Single Cell Level

Published on: November 2, 2020

5.9K

Related Concept Videos

Cardiomyopathy III: Hypertrophic Cardiomyopathy01:29

Cardiomyopathy III: Hypertrophic Cardiomyopathy

Hypertrophic cardiomyopathy, or HCM, is an autosomal dominant genetic disorder characterized by asymmetric left ventricular hypertrophy without ventricular dilation. It is more common in men and is typically diagnosed in young, athletic adults.EtiologyHCM is primarily genetic and is caused by mutations in genes encoding sarcomeric proteins. Researchers have identified over 1400 mutations across at least 11 different genes. Among these, the most frequently occurring mutations are found in the...
87
Cardiomyopathy V: Interprofessional Care01:29

Cardiomyopathy V: Interprofessional Care

Managing cardiomyopathy involves addressing underlying or precipitating causes, treating heart failure with medications, and implementing dietary changes and a balanced exercise and rest regimen.Lifestyle ModificationsCardiomyopathy patients should adopt a low-sodium diet to reduce fluid retention and manage heart failure. A personalized exercise and rest plan helps maintain physical fitness without overstraining the heart. Avoiding alcohol and tobacco is essential to prevent further damage to...
63
Cardiomyopathy II: Dilated Cardiomyopathy01:30

Cardiomyopathy II: Dilated Cardiomyopathy

Dilated cardiomyopathy, or DCM, is a progressive myocardial disorder characterized by ventricular chamber dilation and contractile dysfunction.EtiologyVarious factors can cause DCM, including hypertension and heavy alcohol intake, which contribute to the weakening and enlargement of the heart muscle. Viral infections, such as Coxsackievirus B, adenoviruses, and influenza, can lead to DCM by causing inflammation and damage to heart tissue. Certain chemotherapeutic agents, including daunorubicin,...
61
Cardiomyopathy IV: Restrictive Cardiomyopathy01:29

Cardiomyopathy IV: Restrictive Cardiomyopathy

Restrictive cardiomyopathy (RCM) is a rare heart muscle disease characterized by impaired ventricular filling due to stiffened ventricular walls, leading to significant diastolic dysfunction.EtiologyRestrictive cardiomyopathy can arise from both inherited and acquired diseases, many of which are systemic. It is categorized into four main types: infiltrative, storage, non-infiltrative, and endomyocardial diseases.Infiltrative diseases, such as amyloidosis, lead to RCM by depositing amyloid...
98
Cardiomyopathy I: Introduction and Classification01:25

Cardiomyopathy I: Introduction and Classification

Cardiomyopathy, or CMP, is a group of diseases affecting the myocardial structure, impairing its ability to pump blood effectively. This condition can lead to arrhythmias, heart failure, or sudden cardiac death.Cardiomyopathies are classified into primary and secondary categories:Primary Cardiomyopathy refers to conditions involving only the heart muscle that are often idiopathic (of unknown cause) or genetic. They primarily affect the myocardium without the involvement of other systemic...
119
Myocarditis III: Medical Management01:14

Myocarditis III: Medical Management

Myocarditis: Comprehensive Medical ManagementMyocarditis, the heart muscle inflammation, requires a comprehensive medical management strategy that addresses the underlying cause, provides supportive care, manages symptoms, and reduces cardiac workload.Infections and Autoimmune CausesAdminister appropriate antimicrobial therapy when an infectious agent causes myocarditis. For instance, penicillin treats infections caused by Group A Streptococcus. In cases where autoimmune processes are...
30